Secretome Therapeutics, a Dallas, TX-based biotechnology firm advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), raised $20.4M in funding.
Backers weren’t disclosed.
The corporate intends to make use of the funds to help operations by mid-2026 and fund key initiatives, together with:
- Scientific trials: Launching two Part 1 trials of STM-01 in HFpEF (coronary heart failure with preserved ejection fraction) and DCM (dilated cardiomyopathy), with knowledge anticipated in Q3 2025.
- Manufacturing scale-up: Transitioning STM-01 manufacturing to three-d bioreactor expertise.
- Pipeline improvement: Advancing STM-21 and different preclinical applications to handle inflammatory circumstances.
- Regulatory engagement: Defining the regulatory pathway for STM-01 in orphan indications.
- Mental property: Submitting patents on new cell and secretome merchandise following the issuance of composition patents for STM-01 and STM-21.
Led by CEO and President Vinny Jindal, Secretome Therapeutics is growing therapies derived from neonatal cardiac progenitor cells (nCPCs) to handle life-threatening cardiovascular ailments and circumstances pushed by irritation. Its lead drug is STM-01, a first-in-class mobile remedy designed to cut back irritation, inhibit fibrosis, and help tissue restore in DCM and HFpEF. It is usually growing STM-21, a secretome-based therapeutic in preclinical improvement for inflammatory circumstances, together with pores and skin wounds and co-morbidities of diabetes.
FinSMEs
25/11/2024
